Pasvolsky, O., Dima, D., Feng, L., Dong, W., Richards, T., Davis, J. A., … Grajales-Cruz, A. (2024). Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. In Blood (Vol. 144, pp. 934–934). American Society of Hematology. https://doi.org/10.1182/blood-2024-205989

Pasvolsky, Oren, Danai Dima, Lei Feng, Wenli Dong, Tiffany Richards, James A. Davis, Aimaz Afrough, et al. “Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium.” In Blood, 144:934–934. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-205989.

Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, et al. Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. In: Blood. American Society of Hematology; 2024. p. 934–934.

Pasvolsky, Oren, et al. “Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 934–934. Crossref, doi:10.1182/blood-2024-205989.

Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Khouri J, Curet FNC, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Atrash S, McGuirk JP, Sborov DW, Voorhees PM, Anwer F, Alsina M, Freeman CL, Garfall AL, Sidana S, Cowan AJ, Anderson LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood. American Society of Hematology; 2024. p. 934–934.